Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) vixarelimab met its primary efficacy endpoint in Phase 2a trial in patients with prurigo nodularis.

Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on the skin. Vixarelimab is a monoclonal antibody designed to mediate cytokines implicated in pruritus, inflammation and fibrosis.

The 49-patient trial met its primary efficacy endpoint, where the reduction in weekly-average worst itch numeric rating scale, or WI-NRS, from baseline at week 8 was statistically significantly greater in patients who received vixarelimab versus those who received placebo.

“In addition to the nearly 70% reduction in the median weekly-average WI-NRS at week 8, a disease severity benefit was seen, with approximately a third of vixarelimab-treated patients attaining a clear or almost clear lesion score by week 8,” Dr. John Paolini, Kiniksa’s CMO, said in a statement.

“Vixarelimab has demonstrated encouraging results in both pruritus and nodule response and has the potential to positively impact the lives of patients with prurigo nodularis,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.